2qki: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:
|PDB= 2qki |SIZE=350|CAPTION= <scene name='initialview01'>2qki</scene>, resolution 2.40&Aring;
|PDB= 2qki |SIZE=350|CAPTION= <scene name='initialview01'>2qki</scene>, resolution 2.40&Aring;
|SITE=  
|SITE=  
|LIGAND= <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=BR:BROMIDE+ION'>BR</scene>, <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene> and <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>
|LIGAND= <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=BR:BROMIDE+ION'>BR</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene>
|ACTIVITY=  
|ACTIVITY=  
|GENE=  
|GENE=  
|DOMAIN=
|RELATEDENTRY=[[2a74|2A74]], [[2ice|2ICE]], [[2a73|2A73]], [[2i07|2I07]], [[2icf|2ICF]], [[1a1p|1A1P]]
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2qki FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2qki OCA], [http://www.ebi.ac.uk/pdbsum/2qki PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2qki RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and the exact mode of action of compstatin are unknown. Here we present the crystal structure of compstatin in complex with C3c, a major proteolytic fragment of C3. The structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5. This binding site is part of the structurally stable MG-ring formed by domains MG 1-6 and is far away from any other known binding site on C3. Compstatin does not alter the conformation of C3c, whereas compstatin itself undergoes a large conformational change upon binding. We propose a model in which compstatin sterically hinders the access of the substrate C3 to the convertase complexes, thus blocking complement activation and amplification. These insights are instrumental for further development of compstatin as a potential therapeutic.
Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and the exact mode of action of compstatin are unknown. Here we present the crystal structure of compstatin in complex with C3c, a major proteolytic fragment of C3. The structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5. This binding site is part of the structurally stable MG-ring formed by domains MG 1-6 and is far away from any other known binding site on C3. Compstatin does not alter the conformation of C3c, whereas compstatin itself undergoes a large conformational change upon binding. We propose a model in which compstatin sterically hinders the access of the substrate C3 to the convertase complexes, thus blocking complement activation and amplification. These insights are instrumental for further development of compstatin as a potential therapeutic.
==Disease==
Known diseases associated with this structure: C3 deficiency OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120700 120700]], Macular degeneration, age-related, 9 OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=120700 120700]]


==About this Structure==
==About this Structure==
Line 29: Line 29:
[[Category: Janssen, B J.C.]]
[[Category: Janssen, B J.C.]]
[[Category: Lambris, J D.]]
[[Category: Lambris, J D.]]
[[Category: ACE]]
[[Category: BR]]
[[Category: GOL]]
[[Category: K]]
[[Category: NH2]]
[[Category: c3]]
[[Category: c3]]
[[Category: complement inhibitor design]]
[[Category: complement inhibitor design]]
Line 40: Line 35:
[[Category: immunity]]
[[Category: immunity]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 18:26:51 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 04:50:16 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA